TELEPERFORMANCE 46.050 € (-6,99 %)
VALLOUREC 20.190 € (+2,88 %)
STMICROELECTRONICS 27.510 € (+1,89 %)
BNP PARIBAS ACT.A 82.940 € (-0,49 %)
SOCIETE GENERALE 63.520 € (-0,50 %)
AKZO NOBEL 48.940 € (+1,33 %)
SCHNEIDER ELECTRIC 241.800 € (-0,62 %)
ADYEN 888.500 € (+1,21 %)
LVMH 460.750 € (-1,25 %)
CARREFOUR 15.330 € (+2,17 %)
WINAMP GROUP 0.496 € (-6,42 %)
EXOR NV 63.500 € (-1,85 %)
ARCELORMITTAL SA 45.230 € (+2,31 %)
LEGRAND 135.500 € (+0,63 %)
SOITEC 50.700 € (-2,20 %)
CREDIT AGRICOLE 16.105 € (-0,46 %)
ORANGE 17.200 € (+1,42 %)
BE SEMICONDUCTOR 184.100 € (+0,85 %)
TOTALENERGIES 77.210 € (+1,59 %)
AHOLD DEL 40.530 € (+1,17 %)
WOLTERS KLUWER 62.560 € (-1,97 %)
SANOFI 77.770 € (+1,22 %)
ING GROEP N.V. 21.775 € (-1,43 %)
ESSILORLUXOTTICA 192.750 € (-0,16 %)
VINCI 127.350 € (+0,55 %)
CAPGEMINI 96.360 € (-1,91 %)
SHELL PLC 39.925 € (+2,90 %)
CATERING INTL SCES 13.300 € (+3,10 %)
TECHNIP ENERGIES 34.100 € (0,00 %)
EXOSENS 61.800 € (-2,06 %)
DSM FIRMENICH AG 58.940 € (+1,41 %)
HEINEKEN HOLDING 60.800 € (-0,33 %)
AXA 37.900 € (+0,08 %)
BUREAU VERITAS 26.000 € (0,00 %)
POUJOULAT 8.000 € (+2,04 %)
SAINT GOBAIN 70.420 € (-0,56 %)
BOLLORE 4.850 € (0,00 %)
ABN AMRO BANK N.V. 26.760 € (-0,41 %)
VOPAK 45.620 € (+0,53 %)
SAFRAN 282.100 € (-1,81 %)
CRCAM NORM.SEINE 131.600 € (-2,79 %)
EURONEXT 135.100 € (+1,66 %)
VIVENDI SE 1.689 € (-0,50 %)
PERNOD RICARD 62.900 € (-1,16 %)
RUBIS 33.280 € (+1,09 %)
SCOR SE 30.120 € (-0,07 %)
ARKEMA 54.300 € (+2,55 %)
NN GROUP 65.620 € (-0,36 %)
ASR NEDERLAND 58.200 € (+0,45 %)
ASML HOLDING 1 201.600 € (+2,23 %)
MOULINVEST 24.000 € (+1,69 %)
CORBION 18.340 € (+1,55 %)
TF1 6.920 € (0,00 %)
HIGH CO 3.490 € (-1,41 %)
UMG 15.465 € (-1,72 %)
WORLDLINE DS 0.560 € (-19,56 %)
BOURSE DIRECT 4.450 € (-1,98 %)
HEINEKEN 65.720 € (-0,03 %)
AALBERTS NV 30.360 € (-0,46 %)
OREGE 0.290 € (-2,68 %) |
17/03/2026 13:05
Golden Helix Partners with the Austrian Human Genetics Labs to Drive Advancements in Genomic MedicineEQS-News: Golden Helix, Inc. / Key word(s): Agreement BOZEMAN, Mont., March 17, 2026 /PRNewswire/ -- Golden Helix, a global leader in bioinformatics solutions for Next-Generation Sequencing (NGS) and precision medicine, is proud to announce a strategic agreement with the Austrian public medical genetics labs. The agreement aims to enhance the genomic capabilities of multiple laboratories within the country, supporting critical advancements in cancer and hereditary disease diagnostics. ![]() In a unified effort across Austria's healthcare regions, the six designated Centres for Medical Genetics in Austria are committed to interconnecting their existing Golden Helix's high-quality genomic technologies into harmonized clinical workflows to improve patient outcomes. With a longstanding relationship spanning over a decade, this multi-year agreement solidifies the trust and commitment between Golden Helix and these institutions, driving state-of-the-art patient care in genomic medicine. Prof. Dr. med. Zschocke, PhD, Chair of the Austrian Society of Human Genetics (ÖGH) and Professor of Human Genetics of the Medical University Innsbruck: "This agreement with Golden Helix ensures optimal access to Golden Helix's state-of-the-art NGS diagnostic capabilities. We will leverage this in routine diagnostics across all labs, as well as part of the key infrastructure of the Human Genome Project here in Austria. In that regard, the ability to run the software as a medical device in DX mode is key to our routine testing efforts. At the same time, we leverage scalable and high-performing software to run research projects on human genomes at a country-wide scale." Dr. Laccone, Head of the Clinical Section, Institute of Medical Genetics, at the Medical University of Vienna, said: "We have been working with Golden Helix for over a decade. It is my distinct pleasure to see the relationship grow over all these years. We are excited to enter a new era of human diagnostics that includes also long-read sequencing besides our well-established tests based on short-read technology." Andreas Scherer, PhD, President & CEO of Golden Helix, expressed his gratitude for the collaboration: "We are humbled by this incredible commitment to Golden Helix by entering into the partnership with the Austrian Medical Genetics Labs. We have over a decade of experience working with labs in that region. We are delighted to take our collaborative efforts to deliver clinical diagnostics and personalized care to the next level." Golden Helix's software solutions are trusted by institutions worldwide, from clinical labs to research organizations, for their ability to streamline genomic data analysis and support scalable, high-quality workflows. This collaboration further underscores Golden Helix's leadership in empowering healthcare providers with tools to advance precision medicine globally. About the Austrian Centres of Medical Genetics About Golden Helix Persephone Fossi Logo - https://mma.prnewswire.com/media/1227873/Golden_Helix_Logo.jpg
![]() 17.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2292878 17.03.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière

